INFO & CONTACTS:  +39 02 2390 1

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Lo Russo Giuseppe

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: Pembrolizumab

Mk2870 (sacituzumab tirumotecan)

Chemio: Carboplatin, cisplatin, pemetrexed, paclitaxel, gemcitabine (based on squamous or non-squamous histology)

ClinicalTrials.gov: Read more about clinical trials

Multicenter, open-label study that will evaluate the efficacy and safety of investigational agents with various combinations of chemotherapy and pembrolizumab in participants with newly diagnosed resectable Stages II to IIIB (N2) NSCLC (squamous and nonsquamous). 

The neoadjuvant phase involves two treatment arms: 

  • Arm 1 (standard): Pembrolizumab + platinum based doublet 
  • Arm 2 (sperimental): Pembrolizumab + MK2870 

All patients will undergo surgery and adjuvant treatment with pembrolizumab.

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe